The primary objective is to assess the proportion of hypertensive patients with at least one CV risk factor enrolled in the study who achieve the JNC 7 treatment goals (BP <140/90 mmHg) in a primary-care setting at week 52 (V4). [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The overall assessment of treatment by patients at 52 weeks [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The overall assessment of treatment by physicians at 52 weeks [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

Compliance of patients during the whole study duration (treated by internists and cardiologists as primary physician) [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

Achievement of the JNC 7 treatment goals during the whole study duration (treated by internists and cardiologists as primary physician) [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The difference in systolic blood pressure before and after the month of Ramadan [ Time Frame: 1 month ] [ Designated as safety issue: No ]

The difference in diastolic blood pressure before and after the month of Ramadan [ Time Frame: 1 month ] [ Designated as safety issue: No ]

The percentage of patients achieving JNC 7 treatment goals at the end of the 1 year treatment duration [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The percentage of patients achieving JNC 7 treatment goals (BP <130/80 mmHg in patients with diabetes or chronic kidney disease or BP <140/90 mmHg in all other patients) after 1 year of treatment [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The percentage of patients achieving JNC 7 treatment goals after Ramadan (V3) in fasting and non-fasting patients [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The difference in systolic and diastolic blood pressure before and after the month of Ramadan in individual patients and cohorts [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The compliance and percentage of patients achieving JNC 7 treatment when treated by internists and cardiologists as primary physician [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The overall assessment of treatment by patients and physicians at 52 weeks [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]

The frequency and type of adverse events evaluation of ARBs when given in combination with CCBs [ Time Frame: up to 52 weeks ] [ Designated as safety issue: Yes ]

The difference in CV events between different medications used in the study [ Time Frame: up to 52 weeks ] [ Designated as safety issue: Yes ]

Treatment Adherence to JNC 7(Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 7th Report) Guidelines in Cardiovascular (CV)-Risk Patients Across the Middle East - the Impact of Ramadan Fasting on Achieving Treatment Goals in Daily Practice

Brief Summary

This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists. In this study, patients with essential hypertension and at least one additional risk factor will be included. Patients may take any antihypertensive treatment which is approved for cardiovascular protection including Micardis 80 mg / Micardis Plus. Patients will be followed over one year in four visits from baseline to endpoint with an additional visit before and after the month of Ramadan.

Detailed Description

Purpose:

Study Type ICMJE

Observational

Study Design ICMJE

Observational Model: Case-OnlyTime Perspective: Prospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Non-Probability Sample

Study Population

Hypertensive patients wih at least one CV risk factor

Condition ICMJE

Hypertension

Intervention ICMJE

Not Provided

Study Group/Cohort (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ICMJE

Completed

Enrollment ICMJE

1674

Completion Date

July 2014

Primary Completion Date

July 2014 (final data collection date for primary outcome measure)

Eligibility Criteria ICMJE

Inclusion criteria:

Male or female of age 18 years or older;

Newly diagnosed and untreated or previously treated and uncontrolled patients with essential hypertension;